Filing Details

Accession Number:
0001415889-22-000405
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-05 20:00:37
Reporting Period:
2022-01-03
Accepted Time:
2022-01-05 20:00:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479419 Kala Pharmaceuticals Inc. KALA Pharmaceutical Preparations (2834) 270604595
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1710969 Mary Reumuth C/O Kala Pharmaceuticals, Inc.
1167 Massachusetts Avenue
Arlington MA 02476
Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-01-04 2,850 $1.30 133,208 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2022-01-03 153,000 $0.00 153,000 $1.37
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
153,000 2032-01-03 No 4 A Direct
Footnotes
  1. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. Includes 53,611 unvested RSUs.
  4. This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.